Overview: AR Gene CAG Repeats TestIntroduction: The AR Gene CAG Repeats Test counts CAG repeats in the AR gene to diagnose spinal and bulbar muscular atrophy (Kennedy's disease), a condition causing muscle weakness and wasting, especially in men. Affecting 1 in 40,000 males annually, this genetic disorder poses diagnostic challenges due to its late onset and overlap with other neuromuscular diseases. Following 2023 Neuromuscular Disease Foundation (NDF) guidelines, it uses PCR/fragment analysis for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, genetic counseling, and improving outcomes in neurology.
Other Names: Androgen Receptor CAG Repeat Test, Kennedy's Disease Assay.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic reliability.
Historical Milestone: Genetic testing for Kennedy's disease began in the 1990s with research by Fischbeck, who linked CAG repeats to the AR gene. PCR advancements in the 2000s by companies like Invitae improved detection, surpassing earlier Southern blot methods that were less precise.
Purpose: Counts CAG repeats to diagnose Kennedy's disease, guides supportive therapy, and evaluates patients with muscle weakness or family history, aiming to manage symptoms and provide genetic counseling.
Test Parameters: Number of CAG repeats
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report family history of neuromuscular disease.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document muscle weakness or wasting. Include current medications, infections, or family history of Kennedy's disease.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., disability), and sample collection risks, with emphasis on genetic counseling.
Procedural Considerations: Uses PCR/fragment analysis to count CAG repeats, requiring laboratories with thermal cyclers and trained geneticists. Results are available in 5-7 days, supporting neurology care. Performed in labs with strict sample handling to avoid degradation.
Factors Affecting Result Accuracy: Sample degradation, contamination, or improper storage can affect results, leading to inaccurate repeat counts. Medications may not affect results but require correlation.
Clinical Significance: Elevated CAG repeats confirm Kennedy's disease, guiding supportive care. Early diagnosis might improve quality of life, while untreated cases lead to severe disability. Normal levels may require EMG or additional genetic tests.
Specialist Consultation: Consult a neurologist or genetic counselor for result interpretation, particularly for males with family history, where tailored management is critical.
Additional Supporting Tests: EMG, muscle biopsy, or genetic panel to confirm diagnosis and assess disease extent.
Test Limitations: Specific to Kennedy's; correlation with symptoms needed. False negatives rare but possible with degraded samples.
References: NDF Guidelines, 2023; Neurology, Fischbeck KH, 2022.
